Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | AHCY | P23526 | 6/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12281130 | 1.00 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL12280533 | 0.91 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL29523112 | 0.87 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL22787607 | 0.87 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL2418406 | 0.84 | AHCY (0.57) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL12321456 | 0.83 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL12280353 | 0.83 | AHCY (0.59) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL18589146 | 0.81 | ADK (0.48) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL18297504 | 0.81 | ADK (0.48) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL19050215 | 0.80 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| EP-1993553-B1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY SCIENCE TECH & RES (SG) | 2013-05-08 | — | — | EP | disclosed |
| EP-2522352-A1 | Methods for cancer therapy and stem cell modulation | Agency for Science, Technology and Research (SG) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522352-A1 | Methods for cancer therapy and stem cell modulation | Agency for Science, Technology and Research (SG) | 2012-11-14 | — | — | EP | disclosed |
| US-8211869-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-07-03 | — | — | US | disclosed |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-03-29 | — | — | US | disclosed |
| US-8058258-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-11-15 | — | — | US | disclosed |
| US-8058258-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-11-15 | — | — | US | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | MCL1, BCOR, BCL2 | PI4KA 3644/4885PI4K2B 3349/4885PI4K2A 3665/4885 |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | HCCS, MCL1, AHR | PI4KA 3573/4885PI4K2B 3188/4885PI4K2A 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.